Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine ...

Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), will share results of ...

CHICAGO — June 5, 2017 — For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute-funded SWOG clinical trials program has added 3.34 million years of life ...

Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management Center (SDMC) ...

SWOG Cancer Research Network and its charitable arm, The Hope Foundation for Cancer Research, have jointly developed a website for SWOG Clinical Trials Partnerships (SWOG CTP) as a public resource for ...

The Lancet study shows addition of bortezomib significantly improves survival in treatment-naïve patients with multiple myeloma. In treatment-naïve patients with multiple myeloma, including ...

SWOG’s network of investigators at more than 1,300 sites across the United States can collaborate with Foundation Medicine on biomarker-driven research and clinical trials, as well as access the ...

The 2026 ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Michael Ong discussing TRIPLE-SWITCH (SWOG/CCTG-PR26), a randomized phase III clinical ...

A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or ...

Foundation Medicine, Inc., a global, patient-focused precision medicine company, and SWOG Clinical Trials Partnerships (SWOG CTP) today announced a strategic partnership to advance biomarker-driven ...